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Objective: In most settings, less than 25% of patients with treatment-resistant schizophrenia
receive clozapine, the only medication proven effective for treatment-resistant schizophrenia.
Therefore, a business case analysis was conducted to assess whether increasing clozapine
utilization for treatment-resistant schizophrenia in a health care system would result in direct
health care cost savings.
Methods: Veterans with treatment-resistant schizophrenia who were treated in the Veterans
Health Administration (VHA) were studied. Treatment response, suicides, adverse drug reactions
(and associated mortality), and effects on inpatient hospitalization related to clozapine were
derived from a systematic review of published studies. A one-factor sensitivity analysis and a
probabilistic sensitivity analysis (PSA) with Monte Carlo simulation were conducted to calculate
the cost-benefits of increased clozapine utilization.
Results: Despite monitoring costs, in the base case analysis, the VHA would save $22,444 per
veteran with treatment-resistant schizophrenia over the first year of clozapine therapy, primarily
from 18.6 fewer inpatient days per patient. If current utilization was doubled, and 50% of those
veterans continued clozapine treatment for one year, VHA would save an estimated $80 million.
Cost savings were most sensitive to the proportion of treatment-resistant patients who received
clozapine, decrease in inpatient days, cost of inpatient stays, clozapine response rate, and number
of patients with treatment-resistant schizophrenia. In the PSA, initiation of clozapine for all VHA
patients with treatment-resistant schizophrenia who were not currently treated with clozapine
would save at least $290 million in 95% of simulations.
Conclusions: Increased clozapine utilization would result in net cost savings for the VHA.
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Clozapine is the only treatment that has been proven effective for treatment-resistant
schizophrenia (1–11) and the only treatment approved by the U.S. Food and Drug
Administration (FDA) to decrease suicidal behavior associated with schizophrenia (7). However,
clozapine is associated with significant adverse drug reactions (ADRs), requiring compliance
with an FDA-mandated risk mitigation and evaluation strategy program (7). Given the
complexity of the program—which requires patient, prescriber, and pharmacy registration;
weekly blood draws; and seven-day fills for the first six months of therapy—clozapine is
prescribed for only a minority of patients with treatment-resistant schizophrenia (12–17).
Despite evidence demonstrating clozapine’s benefits, use of clozapine in the United States has
steadily declined since the introduction of other second-generation antipsychotics to the U.S.
market (12,13). Within the Veterans Health Administration (VHA), 4% of patients with
schizophrenia receive clozapine (13). Low clozapine utilization is also reported in non-VHA and
international treatment settings (11,14–16). Considering that 20% to 30% of patients have
treatment-resistant schizophrenia, the low rate of utilization of clozapine implies that 82% to
88% of patients with treatment-resistant schizophrenia are receiving less effective antipsychotics.
Given clozapine’s unique effectiveness for treatment-resistant schizophrenia and its potential to
decrease suicidal behaviors and utilization of more costly forms of care, increasing clozapine
utilization could lead to significant cost savings, despite increased monitoring and contact with
the health care system. Therefore, we conducted a cost-benefit analysis with data obtained from a
medical literature review to simulate potential cost savings associated with increasing clozapine
utilization within the VHA. The hypothesis was that potential cost savings, mostly from
decreased inpatient hospital days, would constitute a case for expanding clozapine utilization,
even if achieving such a goal entailed considerable costs and effort.
Methods
Model Design
We developed a simulation on the basis of data from the medical literature to estimate costs
associated with varying degrees of clozapine utilization. The decision model is a tree structure
comparing the choice of whether or not to use clozapine for a treatment-resistant patient at a
3

single decision node over a one-year time horizon, calculated from the perspective of the VHA
(18). In the clozapine arm, subsequent branch points were event nodes that represent likelihood
of response, risk of completed suicide, and risk of serious ADRs resulting in clozapine
discontinuation (Figure 1). In the clozapine arm, nonresponse was assumed to lead to clozapine
discontinuation. We modeled only serious ADRs (agranulocytosis, seizures, diabetic
ketoacidosis, myocarditis, and ileus) that have been attributed to clozapine use (7). [Figure 1]
In the nonclozapine arm, suicide risk was modeled at a single branch point, and we assumed that
there would be no ADRs, even though other medications cause ADRs. This is a simplifying
assumption, but a conservative model was chosen to decrease the likelihood of overestimating
the benefits of clozapine treatment. Costs of inpatient and outpatient psychiatric care, laboratory
monitoring, and health care expenditures related to ADRs were incorporated into the clozapine
arm. Differential mortality risks from completed suicides between the clozapine and
nonclozapine arms and aggregate risks of mortality from clozapine-related ADRs were
calculated.
This study was exempted from review by the XXX Institutional Review Board.
Model Inputs
Response to clozapine.
We conducted a systematic literature search of MEDLINE articles indexed between January 1,
1985, and June 30, 2015, for studies using the terms “clozapine” AND “refractory
schizophrenia” OR “treatment resistant” OR “resistant schizophrenia.” Thirty-nine articles were
evaluated for number of persons given clozapine and clinical response rate (4,19–56). If these
values could not be ascertained from the text or if the subjects were under 18 years of age, the
article was excluded. Response was most commonly defined as a 20% improvement in baseline
score on the Brief Psychiatric Rating Scale, but inclusion of an article was not conditional on this
definition. Of the 39 identified articles, 31 articles comprising 2,571 clozapine patients were
included (4,19–45,47–49) [see online supplement]. We calculated a pooled clozapine response
rate of 51%.
Suicide rate.
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Completed suicide rate was calculated as the product of the annual suicide rate for the U.S.
general population ages 35–64, the standardized mortality ratio from suicide for schizophrenia,
and a published hazard ratio of suicide for male veterans with schizophrenia (57–60). The effect
of clozapine on suicide risk was determined on the basis of a meta-analysis of five studies that
calculated the relative risk of completed suicide associated with use of clozapine. The relative
risk of completed suicide was 2.90 among patients who did not use clozapine compared with
those who used clozapine (61). For this model, reduction in the risk of suicide was applied only
among clozapine responders; nonresponders were assumed to have a similar risk of suicide as
patients receiving nonclozapine antipsychotics.
Clozapine-related ADRs.
Pooled risks and mortality of the clozapine-related ADRs were calculated from studies identified
through the literature review and the clozapine-prescribing information (7,62–64). A pooled risk
of clozapine-related seizures and subsequent risk of discontinuation were calculated from an
analysis of the clozapine patient management system database (64).
Costs of treatment.
Costs for the first year of clozapine treatment were determined to be the cost of laboratory
monitoring and follow-up visits plus the VHA cost of clozapine tablets. On the basis of current
guidelines for monitoring, there are a total of 39 visits over the course of one year of treatment
(weekly for six months and biweekly for the next six months) (7). We used the pricing schedule
used by the Centers for Medicare and Medicaid Services for the 2015 CPT code for a complete
blood cell count with differential cell count and for the evaluation and management code for a
level II visit with a psychiatrist (65). Patients were assumed to be reimbursed $20 for travel costs
by VHA for each follow-up visit. Clozapine costs in the base case were for a total daily dose of
600 mg, based on 2015 VHA pricing of 41 cents for a 100-mg tablet.
Costs of ADRs.
The estimated cost of the ADRs was the sum of annual direct health care costs (prescriptions,
inpatient treatment, emergency services, outpatient treatment, and office-based medical visits).
Adults with relevant three-digit ICD-9-CM codes and Clinical Classification Software codes
were identified through examination of the Medical Expenditure Panel Survey from 2002 to
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2011 for condition-related annual health care expenditures (66). For diabetic ketoacidosis, costs
were for a single inpatient hospitalization rather than yearly costs (67).
Inpatient psychiatric stays and costs.
The length of inpatient stay was calculated from a pooled, random-effects meta-analysis of seven
studies identified in the systematic review (33,34,36,38,39,68,69) [see online supplement]. These
studies evaluated the impact of clozapine therapy on hospital days, using either a prepost
comparison or a comparison between hospital days for intervention and control patients. The cost
of an inpatient stay at a VA hospital was estimated at $1,414 per day (13).
Treatment-eligible population.
In 2009, a total of 87,000 veterans had schizophrenia or schizoaffective disorder (13). Although
20% to 30% of patients are reported to have treatment-resistant schizophrenia, we assumed that
20% of patients, an estimated 18,000 veterans, had treatment-resistant schizophrenia (1).
Assuming that the 3.6% of veterans with schizophrenia already treated with clozapine had
treatment-resistant schizophrenia, we estimated an additional 14,400 veterans with treatmentresistant schizophrenia would be eligible for a clozapine trial.
Cost Reporting
For each parameter, costs that were not already in 2015 U.S. dollars were inflated to 2015 U.S.
dollars by calculating the rate of medical inflation from the Consumer Price Index (CPI) between
the year in which the parameter was reported and 2014 (last available year of the CPI) and then
adjusting again by the average yearly rate of medical inflation from 2010 to 2014 (70).
Analysis
This analysis was a cost-benefit model, comparing costs and monetizing benefits associated with
clozapine use and nonuse in treatment-resistant schizophrenia. The deterministic base case model
used the parameter estimates for the model inputs detailed above to determine the difference in
costs for treatment-resistant schizophrenia between clozapine treatment and nonuse of clozapine.
In the clozapine arm, the costs of treatment, ADRs, and inpatient stays were summed. In the
nonclozapine arm, it was assumed that ADRs did not occur and medications had no costs, so the
costs reflected inpatient stays. Mortality was estimated by the effect of clozapine on suicide
among veterans and anticipated mortality from serious ADRs (61–63). The business case for
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clozapine was broadened by multiplying the results over the treatment-eligible population within
the VHA.
Several assumptions were made for model variability. Costs of expenditures directly
attributable to clozapine use (prescriptions, laboratory monitoring, office visits, and treatment of
serious ADRs) were not included in the control arms. Health care expenditures unrelated to
clozapine effects were assumed to be identical in the two arms to prevent needlessly
complicating the model; these expenditures included metabolic monitoring, which is
recommended for all patients on antipsychotics. Benefits of reduced inpatient stay and
diminished incidence of completed suicide were applied only for clozapine responders. Costs of
clozapine treatment were incurred for the entire year for clozapine responders and were prorated
until day of discontinuation for nonresponders. All costs for persons who died by suicide were
curtailed at the day of suicide. ADR costs were prorated from the day on which the ADR
occurred until the end of the year, with the exception of diabetic ketoacidosis, which was
assumed to be a single event. In the base case deterministic model, suicide, clozapine
discontinuation due to nonresponse, and ADRs occurred at six months, the midpoint of the year
(day 183). Among clozapine responders, the ADRs were assumed to lead to discontinuation,
except seizures, in which case we used published rates of discontinuation of clozapine following
a seizure to estimate the proportion of patients who would continue clozapine (64). For clozapine
nonresponders, all ADRs were assumed to result in drug discontinuation.
To incorporate uncertainty, one-factor sensitivity analyses and a probabilistic sensitivity
analysis (PSA) with Monte Carlo simulation were calculated (71). In the factor analysis, we
varied the range of input parameters by 20% in each direction from the base case, except the
proportion of treatment-resistant schizophrenia patients initiated on clozapine, which were varied
from 20% to 80%. We then evaluated the relative influence of high and low values for each input
on cost savings for the health care system. For the PSA, method of moments were used to fit
probability parameters on beta distributions, relative risk and hazard ratios on log normal
distributions, and event days (ADRs, clozapine discontinuation, and suicide). Fixed costs (lab
monitoring, veteran travel, and psychiatrist visits) were varied on uniform distributions. Gamma
distributions were used to fit aggregate ADR costs, and Poisson distributions were used to fit
inpatient days (Table 1). Random numbers generated output values within distributional
assumptions. Simulated cost outcomes were determined for the entire health care system, with
7

1,000 replications each for initiation of clozapine among 20%, 40%, 60%, and 80% of patients
with treatment-resistant schizophrenia. The last of these proportions would equate to 100%
clozapine use because it would be added to the current rate of use of clozapine for treatmentresistant schizophrenia, which is approximately 20%. Simulations and analysis were performed
by using Excel 2010 and Stata, version 13, software packages.
Results
Cost Savings
If 20% of veterans with treatment-resistant schizophrenia initiated clozapine, the one-year costs
to the VHA would decrease by a mean of $22,444 per patient treated with clozapine. Savings
were driven primarily through an average reduction of 18.6 inpatient hospital days. If current
utilization was doubled and 50% of those veterans continued clozapine treatment for one year,
the VHA would accrue an estimated cost savings of $80 million (Table 2).
ADRs
An additional 743 serious ADRs would occur in year 1 if all veterans with treatment-resistant
schizophrenia who had previously not been treated with clozapine initiated clozapine treatment.
If only 20% of those veterans began treatment with clozapine, an additional 149 serious ADRs
would occur (Table 2).
Deaths
If all veterans with treatment-resistant schizophrenia who had not been treated with clozapine
later initiated clozapine, 19 suicides would be averted annually, and there would be a total of 18
additional deaths, three due to clozapine-related agranulocytosis and 15 due to ileus. If only 20%
of veterans with treatment-resistant schizophrenia who had not previously initiated clozapine
began treatment with clozapine, there would be three deaths due to clozapine-related ADRs and
three fewer suicides in the clozapine group versus the nonclozapine group. Greater increases in
clozapine use would lead to more lives saved by suicide prevention than lives lost to clozapineassociated ADRs.
Sensitivity Analysis
One-way sensitivity analysis was performed, varying each of the model inputs across a plausible
range to evaluate the input’s influence on our findings. Cost savings were most sensitive to
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changes in the proportion of patients with treatment-resistant schizophrenia who received
clozapine (92% of the swing in range of costs), reduction in inpatient days (2%), cost of inpatient
stay (2%), rate of response to clozapine (2%), and number of patients with treatment-resistant
schizophrenia (2%) (Figure 2). Costs associated with laboratory monitoring, ADRs, outpatient
visits, and travel had negligible impact on costs for the payer. Probabilistic sensitivity analysis
confirmed that increasing the number of patients with treatment-resistant schizophrenia receiving
clozapine would result in incremental cost savings. Assuming a baseline rate of 20% for
clozapine utilization, cost savings increased to $323,188 million when 100% of patients with
treatment-resistant schizophrenia were prescribed clozapine.
Figure 3 shows the cost implications of initiating clozapine for 20% to 80% of patients with
treatment-resistant schizophrenia (representing 100% utilization at beginning of year 1, including
current users). A relatively modest change, doubling utilization from 20% to 40% of eligible
patients, would lead to cost savings of more than $80 million in the first year of treatment. In
95% of simulations, increasing clozapine utilization from 20% to 40% of eligible patients saved
a minimum of $72 million in the first year. Initiation of clozapine for all VHA patients with
treatment-resistant schizophrenia who were not currently treated with clozapine would save at
least $290 million in 95% of simulations.
Discussion
Clozapine has repeatedly demonstrated superiority to other antipsychotics for treatment-resistant
schizophrenia, but it is underutilized. Therefore, we simulated the effects of increasing clozapine
utilization for patients with treatment-resistant schizophrenia. Doubling the proportion of
patients with treatment-resistant schizophrenia who received clozapine from 20% to 40% would
save $80 million for the VA, without considering any value accruing to patients from improved
outcomes. In addition, despite the much-feared adverse effects of clozapine, the increase in
ADR-related mortality associated with clozapine would be more than offset by suicide
prevention.
The benefits of increased clozapine utilization may have been underestimated because of
several assumptions. First the model assumed that 20% of patients with schizophrenia have
treatment-resistant schizophrenia, although many studies have estimated a rate as high as 30%
(1). Second, the costs of clozapine treatment are substantially higher in the first year compared
with later years because of a need for more office visits and laboratory monitoring. After the first
9

year, the continued costs of clozapine treatment are more similar to those of other antipsychotics,
but the benefits of clozapine treatment continue to accrue. In addition, this model assumed that
treatment with other antipsychotics did not result in serious ADRs or include prescription or
other treatment costs. Thus it is possible savings could be higher than reported in this study.
Our analyses had several important uncertainties. First, it was difficult to estimate the
incidence and costs of obesity and diabetes risk and the expected increased risk in cardiovascular
mortality and morbidity associated with use of clozapine. Some comparator agents have similar
risks, whereas most have substantially lower risks than clozapine (72). In addition, studies have
reported mixed effects of clozapine on mortality (73–75). As such, cardiometabolic ADRs were
not included in the analyses. Second, it should be remembered that extrapolation of cost savings
to subsequent years and to use outside the VHA is uncertain. Third, some of the studies
providing evidence for clozapine benefits were conducted years ago and thus may be less
relevant to current practice. Finally, the base model assumed a reduction of 30 inpatient days in
the first year. Although that may seem extreme in an era of shortened hospitalizations, the
average length of stay for schizophrenia both within and outside the VHA in 2009 and 2011 was
approximately 21 days, and patients with treatment-resistant schizophrenia averaged three
hospitalizations per year (13,76). In addition, studies indicate that more severe illness, as would
be expected with treatment-resistant schizophrenia, further increases the length of stay (76). Thus
it is reasonable to assume that clozapine would be associated with 30 days of inpatient
hospitalization. Varying the analyses by limiting the number of days of hospitalization avoided
to seven still resulted in cost savings [see online supplement].
This study had important strengths. A number of underlying assumptions suggest that, if
anything, benefits of increased clozapine utilization have been underestimated. In addition, much
is known about the improved outcomes, adherence, and persistence rates associated with
clozapine treatment (75,76). However, the study also had some limitations. First, all the data
were not from the VHA or specifically related to treatment-resistant schizophrenia. For example,
the suicide rate was not based on rates for schizophrenia populations with treatment-resistant
disease, given the lack of data on suicide among patients with treatment-resistant schizophrenia.
Second, rates of response, ADRs, and costs associated with use of clozapine were based on the
published literature and may not accurately reflect real-world systems. Third, dispensing costs
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were not included, given that we found no estimates that included the added cost of maintenance
and oversight of the VHA clozapine registry.
Clozapine monitoring guidelines have recently changed. It is unlikely that these changes will
have a significant impact on cost of monitoring, but the possibility cannot be excluded. In
addition, monitoring of clozapine serum concentrations is recommended by some guidelines.
Because clozapine serum concentrations are not routinely monitored, we excluded these costs
from our analyses. If completed, such monitoring would be expected to increase clozapine costs.
It is important to note the circumscribed nature of the study. This study was not a cost-utility
analysis and, therefore, did not formally model patient-related outcomes, such as health-related
quality of life. Instead, we opted to conduct a simpler business case analysis from the VHA
perspective, including direct health care costs and veterans’ travel costs but excluding indirect
costs, such as caregiver time and missed work. It should be noted that the value to society from
increased clozapine utilization for treatment-resistant schizophrenia would greatly exceed the
cost savings we reported here because patients and, presumably, their families prefer that the
symptoms of schizophrenia be well controlled (77). However, payers are likely most responsive
to a business case analysis, which is why we chose this approach.
In a separate study, we found that some relatively straightforward strategies were associated
with higher clozapine utilization within the VHA (X). Among these are having a dedicated
clozapine clinic; ensuring that the clinic has sufficient capacity to accommodate all patients with
treatment-resistant schizophrenia and adequate staffing levels by nonphysicians, including
registered nurses and pharmacists; and providing transportation to appointments for patients
using clozapine. Although these strategies are allowable under VHA rules and regulations and
are currently used at some sites, they are not without cost.
It is hoped that this study provides an impetus to make these relatively straightforward, if not
inexpensive, changes. Extrapolating from our findings, an average-sized VHA site (managing
700 schizophrenia patients) could expect to have 140 patients with treatment-resistant
schizophrenia. Increasing the proportion of patients with treatment-resistant schizophrenia who
are treated with clozapine from 20% to 40% would save the facility more than $625,000 in the
first year alone. It is difficult to imagine that the cost of implementing our recommendations
could approach this figure. Thus, even a modest increase in clozapine utilization, achieved at a
very high cost, could still result in a net cost savings for the VHA.
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Conclusions
This study found that modest increases in clozapine utilization could yield significant cost
savings. It is very unusual to have the opportunity to save money while improving patient
outcomes, particularly in such a vulnerable population. Our results suggest that the VHA should
strongly consider initiatives, possibly based on practices already used by high-performing sites,
to substantially increase clozapine utilization for treatment-resistant schizophrenia.
References
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FIGURE 1. Outcomes of a decision model involving whether to initiate clozapine for a patient with treatment-resistant schizophreniaa

a

ADR, adverse drug reaction
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FIGURE 2. Effects of varying the model inputs on the cost of clozapine carea
Input

Cost Impact

Proportion Treated

0.2

0.8

Reduction Inpatient Days|Clozapine Response

-29.8728

-44.8092

Cost -Inpatient Stay(per day)

1130.96

1696.44

Clozapine response rate 0.407761482
Treatment Refractory Schizophrenic Veterans

14400

Cost-Psychiatrist Visits(per event)

52.776

Cost-clozapine tx(daily)

2.952

0.611642223
21600
35.184
1.968

Cost Savings

a

Input parameters were varied from the base case by 20% in each direction, except proportion of patients with treatment-resistant
schizophrenia who were treated with clozapine, which varied from 20% to 80%. Reduced inpatient days were prorated for probability
clozapine response rate. Rates of adverse drug reactions (ADRs), suicide, clozapine discontinuation, costs of ADRs, and laboratory
monitoring had smaller impacts.
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FIGURE 3. Estimated one-year VHA-wide savings and mortality associated with incremental
gains in clozapine utilization among veterans with treatment-resistant schizophreniaa

a

Bars indicate mean, 5th, and 95th percentiles from 1,000 simulations for each incremental
increase of 20%.
∆ non-clozapine suicides
◊ clozapine suicides
o clozapine mortality from ADRs
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TABLE 1. Adjustment of base case values during sensitivity analyses of the cost-benefits of
increased clozapine utilization among veterans with treatment resistant schizophreniaa
Variable
Base case
SD
Distribution
Notes
Veterans with treatment- 18,000
Uniform
2009 VHA estimate of ~90,000
resistant schizophrenia
patients with schizophrenia  20%
rate of treatment-resistant
schizophrenia (13)
Proportion initiated
.20
Uniform
Assumption
clozapine treatment
Probability of clozapine
.510
.01 Β
Pooled meta-analysis of 31 studies
response
(4,19–45,47–49) [see online supplement]
Probability of completed
.003
Β,, log
U.S. suicide rate for ages 35–64 
suicideb
normal
SMR for suicides among persons with
schizophrenia  HR for suicides
among male patients with
schizophrenia (57–60)
Completed suicide rate
.34
.8 Log normal 1/RR (61)c
given clozapine response
[completed
suicide/clozapine
response])
Probability of ADR
(clozapine arm only)
Agranulocytosis
.005
.0002 Β, log
Calculated from Cohen et al., 2012
normal
(63)
Myocarditis
.0001
.000 β
Calculated from Cohen et al., 2012
(63)
Ileus
.004
.0004 β
Calculated from Cohen et al., 2012
(63)
Seizures
.032
.003 β
Calculated from Cohen et al., 2012
(63)
Diabetic ketoacidosis
.0001
.000 β
Calculated from Cohen et al., 2012
(63)
Probability of
.352
046 β
Calculated from Cohen et al., 2012
discontinuation of
(63)
clozapine due to seizures
Probability of mortality
.28
.28 β
Calculated from Cohen et al., 2012
due to ADR
(63)
Myocarditis
β
Agranulocytosis
.03
.007 β
Calculated from Cohen et al., 2012
(63)
Ileus
.20
.036 β
Calculated from Cohen et al., 2012
(63)
Diabetic ketoacidosis
.03
.04 β
Calculated from Cohen et al., 2012
(63)
Fixed costs ($)d
24

Lab monitoring (event)

10.58

Uniform

Psychiatrist visit

43.98

Uniform

20.00
2.46

Uniform
Uniform

1,413.70

Uniform

Veteran travel (event)
Clozapine treatment
(day)
Inpatient stay (day)
Cost for ADR (2015 $)
Seizures (year)

1,621.62

245.75 γ

Myocarditis (year)

3,695.89

934.70 γ

Agranulocytosis (year)

2,428.31

1,641.52 γ

Ileus (year)

6,796.33

1,234.79 γ

Diabetic ketoacidosis
(single hospitalization)
Day of suicide
Day of discontinuation of
clozapine
Day of ADR (clozapine
arm)
Inpatient days

20,141.34 20,415.43 γ

WBC; CPT G0306 (CMS 2015 Lab
Diagnostic Fee Schedule, global,
nonfacility) (64)
CPT 99212 (CMS 2015 Physician Fee
Schedule, global, nonfacility) (64)
Assumption
100-mg tablet, 600 mg/day (VHA
VISN 1 costs)
2009 VHA estimate (2015 $)
MEPS 2002–2011 for adults (ICD-9
code 345) (65)
MEPS 2002–2011 for adults (ICD-9
code 422) (65)
MEPS 2002–2011 for adults (ICD-9
code 288) (65)
MEPS 2002–2011 for adults >18
(ICD-9 code 560 (65)
(67)

183
183

Uniform
Uniform

Assumption
Assumption

183

Uniform

Assumption

138

Poisson

Pooled analysis of 7 studies
(33,34,36,38,39,68,69) [see online
supplement]
e
Reduction in inpatient
–37
Poisson
Unstandardized mean difference in
days among clozapine
inpatient days of 7 studies
responders
(33,34,36,38,39,68,69) [see online
supplement]
a
The base case used assumed or estimated mean values. SDs were used to calculate γ and β
distributional parameters for probabilistic sensitivity analysis. Abbreviations: ADR, adverse drug
reaction; CMS, Centers for Medicare and Medicaid Services; HR, hazard ratio; MEPS, Medical
Expenditure Panel Survey; RR, relative risk; SMR, standard mortality ratio; VISN, Veterans
Integrated Service Network; and WBC, white blood cell count
b
The probability of suicide among veterans with treatment-resistant schizophrenia was a function
of three individual parameters with distributional properties of mean and standard deviation. The
SD variance was calculated from product of component inputs (SMR, HR, and incidence).
c
The suicide rate for clozapine was calculated as the reciprocal of the rate of suicide prevention
in the article by Hennen and Baldessarini (61).
d
Fixed costs did not have an SD but were varied on uniform distributions with a range of ±20%.
e
The SD was the
mean for Poisson distribution.)
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TABLE 2. Simulated outcomes from doubling baseline rates of clozapine utilization at the VHA
for one yeara
Simulated outcome (percentile)
Outcome
Base case
Mean
5th
95th
Aggregate cost and
utilization
Cost ($)
Control arm
700,410,000 695,541,000
633,082,000 757,851,000
Clozapine arm
619,613,000 615,697,000
560,652,000 671,316,000
Cost savings ($)
80,797,000
79,845,000
72,406,000
87,685,000
Inpatient days
Control arm
495,000
492,000
447,920
536,000
Clozapine arm
429,000
426,000
388,000
464,000
Inpatient days saved
67,000
66,000
60,000
72,000
Clozapine responders
1,787
1,794
1,629
1,964
Adverse drug reaction
(ADR)b
Seizures
116
115
94
137
Agranulocytosis
16
16
10
23
Myocarditis
<1
<1
0
1
Ileus
16
16
9
23
Diabetic ketoacidosis
<1
<1
0
2
Mortality
Suicides (control arm)
11
11
6
17
Suicides (clozapine arm)
8
8
3
12
Deaths due to ADRs
Agranulocytosis
<1
<1
0
2
Myocarditis
<1
<1
0
1
Ileus
3
3
1
6
Diabetic ketoacidosis
<1
<1
0
1
a
Estimates are incremental costs, ADRs, and mortality associated with doubling estimated
current clozapine use (deterministic base case analysis). Results are from the probabilistic
simulation of incremental costs of clozapine initiation (clozapine arm) and noninitiation (control
arm) associated with initiating clozapine for an additional 20% of the estimated 18,000 (±10%)
veterans with treatment-resistant schizophrenia who were not currently receiving clozapine.
b
Clozapine arm only. Seizures were assumed to be nonfatal.
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Table 1: Studies included in meta-regression
Author
Year Response Total
Trial
%

Comments

Length(wks)
Treatment-resistant schizophrenia

Small19

1987

40%

38

and non-treatment-resistant
schizophrenia - 55% response

Kane4
Mattes

1988
20

30%

134

6
Based on 8 did substantially better

1989

57%

14

Up to 104
on clozapine

Davidson21

1993

50%

28

5

Kuoppasalmi22 1993

67%

103

26

Based on statement "More than 2/3
improved”

Breier23

1993

60%

30

26

Littrel24

1994

48%

42

12
Treatment-resistant schizophrenia+

Lieberman25

1994

50%

66

52

additional 18 patients not tolerant of
other antipsychotics

Szymanski26

1994

30%

10

Honer27

1995

31%

61

32

Grace28

1996

50%

31

52

Hoff29

1996

14%

30

12

Wilson30

1996

73%

100

48

All improved within 1 week but
followed weekly X 18 weeks the
27

every 3 months for 18 months
Aymard31

1997

100%

7

4-38 months follow-up
Mean follow up 75 weeks

Conley32

1997

68%

50

All responders responded within 8
weeks

Aitchison33
Rosenheck

1997
34

85%

26
Hospital days reduced from 168.1 to

1996

57%

205

52
143.8

Blieden35
Luchins

36

1998

52%

33

26
Cost study, hospital days reduced

1998

75%

28
from 23.5 to 7.6

Sajatovic37

1998

30%

97

60

Buckman38

1999

47%

518

60

Cost Study

Percudani39

1999

80%

15

52

Cost Study

Rosenheck40

1999

39%

122

26

Response at 26 weeks
48 completed 16 weeks, 36 went on

Simpson41

1999

19%

to 2nd and 3rd 16week trials at other

48

doses
Dettling42

2000

81%

26

10

Sajatovic43

2000

58%

522

60

Wahlbeck44

2000

50%

10

10

Kane45

2001

57%

37

29

Narendran46

2003

67%

9

6

50% dropout

28

Honer47

2006

26%

34

8

Semiz48

2007

56%

97

16

Already clozapine poor responders

Pooled Total
51%

2571

*calculate SD from p<0.001
Online Supplemental Material
Table 2: Studies excluded from meta-regression
Author
Year Response Total
Trial
%
Kahn

Comments

Length(wks)
8 responders 11 non-responders all

49

1993

47%

19

5
improved

Jonsson

50

15 patients showed “substantial
1995

70%

21

78
response”

51

Kronig

“responders” more likely to have
1995

40.5%

45

6
serum concentration >350ng/ml
39% (18) low; 61% (23) med; 60%

VanderZwaag52 1996

*

28

12

(15) high concentration groups
responded

Lindenmayer53

1998

*

35

12

No overall response metric
Response rate not defined

Semyak54

2001

*

1415

36

Unclear if treatment-resistant
schizophrenia population

29

Umbricht

55

Secondary analysis of patients in
2002

59%

37

29

Kane trial45
Significant response noted on

Saccchetti

56

PANSS but no response rate for
2009

*

74

18
treatment-resistant schizophrenia
(n=65)
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Table 3: Inpatient hospital days with clozapine use+
Author

Year

Clozapin

Clozapine

Comparato

Comparator

e (N)

Inpatient Days

r

Inpatient

(SD)

(N)

Days
(SD)

Aitchison33*

1997

26

6.5 ± 6.5

26

39.5 ± 39.5

Ghaemi68

1998

20

4.6 ± 11.3

20

47.7 ± 20

1996

205

143.8 ± 143.8

218

168.1 ± 168.1

Luchins36

1998

28

7.6 ± 14.9

28

23.5 ± 49.6

Buckman38*

1999

243

70.8 ± 70.8

243

152.9 ± 152.9

Percudani39*

1999

12

58.8 ± 58.8

12

107.8 ± 58.8

Atkinson69

2007

23

74.1 ± 137.3

23

119.8 ± 143.5

Rosenheck34
*

+

SD assumed to equal the mean inpatient days if not otherwise specified
*calculate SD from p<0.001
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